Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Cell Physiol ; 239(5): e31222, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38375873

RESUMO

Mammalian development commences with the zygote, which can differentiate into both embryonic and extraembryonic tissues, a capability known as totipotency. Only the zygote and embryos around zygotic genome activation (ZGA) (two-cell embryo stage in mice and eight-cell embryo in humans) are totipotent cells. Epigenetic modifications undergo extremely extensive changes during the acquisition of totipotency and subsequent development of differentiation. However, the underlying molecular mechanisms remain elusive. Recently, the discovery of mouse two-cell embryo-like cells, human eight-cell embryo-like cells, extended pluripotent stem cells and totipotent-like stem cells with extra-embryonic developmental potential has greatly expanded our understanding of totipotency. Experiments with these in vitro models have led to insights into epigenetic changes in the reprogramming of pluri-to-totipotency, which have informed the exploration of preimplantation development. In this review, we highlight the recent findings in understanding the mechanisms of epigenetic remodeling during totipotency capture, including RNA splicing, DNA methylation, chromatin configuration, histone modifications, and nuclear organization.


Assuntos
Reprogramação Celular , Metilação de DNA , Epigênese Genética , Células-Tronco Pluripotentes , Células-Tronco Totipotentes , Animais , Humanos , Diferenciação Celular/genética , Reprogramação Celular/genética , Cromatina/metabolismo , Cromatina/genética , Metilação de DNA/genética , Desenvolvimento Embrionário/genética , Regulação da Expressão Gênica no Desenvolvimento/genética , Células-Tronco Pluripotentes/metabolismo , Células-Tronco Totipotentes/metabolismo
2.
Bioact Mater ; 29: 85-97, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37449253

RESUMO

Aging is a degenerative process that leads to tissue dysfunction and death. Embryonic stem cells (ESCs) have great therapeutic potential for age-related diseases due to their capacity for self-renewal and plasticity. However, the use of ESCs in clinical treatment is limited by immune rejection, tumourigenicity and ethical issues. ESC-derived extracellular vesicles (EVs) may provide therapeutic effects that are comparable to those of ESCs while avoiding unwanted effects. Here, we fully evaluate the role of ESC-EVs in rejuvenation in vitro and in vivo. Using RNA sequencing (RNA-Seq) and microRNA sequencing (miRNA-Seq) screening, we found that miR-15b-5p and miR-290a-5p were highly enriched in ESC-EVs, and induced rejuvenation by silencing the Ccn2-mediated AKT/mTOR pathway. These results demonstrate that miR-15b-5p and miR-290a-5p function as potent activators of rejuvenation mediated by ESC-EVs. The rejuvenating effect of ESC-EVs was further investigated in vivo by injection into aged mice. The results showed that ESC-EVs successfully ameliorated the pathological age-related phenotypes and rescued the transcriptome profile of aged mice. Our findings demonstrate that ESC-EVs treatment can rejuvenate senescence both in vitro and in vivo and suggest the therapeutic potential of ESC-EVs as a novel cell-free alternative to ESCs for age-related diseases.

3.
Comput Intell Neurosci ; 2022: 4410075, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35655494

RESUMO

In order to better mine the value of data, the author proposes a research on the automatic access control of big data open resources multimedia based on blockchain and introduces big data access control BBAC-BD (blockchain-based access control mechanism for big data environment). The author designed a strategy management contract based on the Bloom filter, as a probabilistic data structure with extremely high space utilization efficiency and proposed the strategic management contract (PAP CONTRACT) and the strategic decision contract (PDP CONTRACT). In this way, the nontampering, auditability, and verifiability of the access control information are guaranteed; then, the access control method based on smart contracts is adopted to realize the user-driven, whole-process transparent, and dynamic and automatic access control of big data resources. The simulation results show that the greater the ratio of n/k, the better the optimization effect, and the greater the ratio, the lower the corresponding misjudgment rate, but it will also take up more space costs. At the same time, the true value of the false positive rate is generally less than the theoretical value of the false positive rate. When the performance of Hash (strategy to retrieve) is better, the result of Hash distribution is more uniform. Under the condition of m = 3, the misjudgment rate acceptable for the expected use can be achieved, and the increase in the number of Hashes will not bring a significant increase in revenue. Freed from the traditional model of providing access control services based on third parties, solve the problem of transparency of authority judgments; at the same time, through smart contracts, based on the strategy published by the resource owner on the blockchain, realize automatic access control to big data resources; and make the judicial process more flexible and the judgment result more credible. The BBAC-BD mechanism realizes a safe, reliable, and transparent new access control architecture, and it can effectively promote the safe circulation and sharing of big data.


Assuntos
Blockchain , Automação , Big Data , Multimídia
4.
Front Cell Dev Biol ; 10: 882671, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35721479

RESUMO

Mouse embryonic stem cells (ESCs) contain a rare cell population of "two-cell embryonic like" cells (2CLCs) that display similar features to those found in the two-cell (2C) embryo and thus represent an in vitro model for studying the progress of zygotic genome activation (ZGA). However, the positive regulator determinants of the 2CLCs' conversion and ZGA have not been completely elucidated. Here, we identify a new regulator promoting 2CLCs and ZGA transcripts. Through a combination of overexpression (OE), knockdown (KD), together with transcriptional analysis and methylome analysis, we find that Dppa3 regulates the 2CLC-associated transcripts, DNA methylation, and 2CLC population in ESCs. The differentially methylated regions (DMRs) analysis identified 6,920 (98.2%) hypomethylated, whilst only 129 (1.8%) hypermethylated, regions in Dppa3 OE ESCs, suggesting that Dppa3 facilitates 2CLCs reprogramming. The conversion to 2CLCs by overexpression of Dppa3 is also associated with DNA damage response. Dppa3 knockdown manifest impairs transition into the 2C-like state. Global DNA methylome and chromatin state analysis of Dppa3 OE ESCs reveal that Dppa3 facilitates the chromatin configuration to 2CLCs reversion. Our finding for the first time elucidates a novel role of Dppa3 in mediating the 2CLC conversion, and suggests that Dppa3 is a new regulator for ZGA progress.

5.
Mol Ther ; 30(8): 2746-2759, 2022 08 03.
Artigo em Inglês | MEDLINE | ID: mdl-35514086

RESUMO

Although tissue-resident-memory T (TRM) cells, a recently identified non-circulating memory T cell population, play a crucial role in mediating local immune responses and protect against pathogens upon local reinfection, the composition, effector function, and specificity of TRM cells in the kidney and their relevance for chronic kidney disease remain unknown. In this study, we found that renal tissue displayed high abundance of tissue-resident lymphocytes, and the proportion of CD8+ TRM cells was significantly increased in the kidney from patients and mice with focal segmental glomerulosclerosis (FSGS), diabetic kidney disease (DKD), and lupus nephritis (LN). Mechanistically, IL-15 significantly promoted CD8+ TRM cell formation and activation, thereby promoting podocyte injury and glomerulosclerosis. Interestingly, Sparsentan, the dual angiotensin II (Ang II) receptor and endothelin type A receptor antagonist, can also reduce TRM cell responses by intervening IL-15 signaling, exploring its new pharmacological functions. Mechanistically, Sparsentan inhibited Ang II or endothelin-1 (ET-1)-mediated IL-15 signaling, thereby further regulating renal CD8+ TRM cell fates. Collectively, our studies provide direct evidence for the pivotal role of renal CD8+ TRM cells in podocyte injury and further strengthen that targeting TRM cells represents a novel therapeutic strategy for patients with glomerular diseases.


Assuntos
Memória Imunológica , Podócitos , Animais , Linfócitos T CD8-Positivos , Interleucina-15 , Camundongos , Transdução de Sinais
6.
Acta Pharm Sin B ; 11(2): 394-405, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33643819

RESUMO

Recent studies have shown that programmed cell death 4 (PDCD4) modulates distinct signal transduction pathways in different pathological conditions. Despite acute and chronic immune responses elicited by ischemia contributing to the functional deterioration of the kidney, the contributions and mechanisms of PDCD4 in acute kidney injury (AKI) have remained unclear. Using two murine AKI models including renal ischemia/reperfusion injury (IRI) and cisplatin-induced AKI, we found that PDCD4 deficiency markedly ameliorated renal dysfunction and inflammatory responses in AKI mice. Consistently, upregulation of PDCD4 was also confirmed in the kidneys from patients with biopsy confirmed acute tubular necrosis from a retrospective cohort study. Moreover, we found that overexpression of Fgr, a member of the tyrosine kinase family, dramatically aggravated renal injury and counteracted the protective effects of PDCD4 deficiency in AKI mice. We discovered that FGR upregulated NOTCH1 expression through activating STAT3. Most importantly, we further found that systemic administration of ponatinib, a tyrosine kinase inhibitor, significantly ameliorated AKI in mice. In summary, we identified that PDCD4 served as an important regulator, at least in part, of FGR/NOTCH1-mediated tubular apoptosis and inflammation in AKI mice. Furthermore, our findings suggest that ponatinib-mediated pharmacologic targeting of this pathway had therapeutic potential for mitigating AKI.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...